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Abstract 
Background: Adverse drug reactions (ADRs) can occur any time someone uses a medication. ADRs are systematically tracked 
and cataloged, with varying degrees of success, in order to better understand their etiology and develop methods of prevention. 
The US Food and Drug Administration (FDA) has developed the FDA Adverse Event Reporting System (FAERS) for this purpose. 
FAERS collects information from myriad sources, but the primary reporters have traditionally been medical professionals and 
pharmacovigilance data from manufacturers. Recent studies suggest that information shared publicly on social media platforms 
related to medication use could be of benefit in complementing FAERS data in order to have a richer picture of how medications 
are actually being used and the experiences people are having across large populations. 
Objective: The aim of this study is to validate the accuracy and precision of social media methodology and conduct evaluations 
of Twitter ADR reporting for commonly used pharmaceutical agents. 
Methods: ADR data from the 10 most prescribed medications according to pharmacy claims data were collected from both 
FAERS and Twitter. In order to obtain data from FAERS, the SafeRx database, a curated collection of FAERS data, was used to 
collect data from March 1, 2016, to March 31, 2017. Twitter data were manually scraped during the same time period to extract 
similar data using an algorithm designed to minimize noise and false signals in social media data. 
Results: A total of 40,539 FAERS ADR reports were obtained via SafeRx and more than 40,000 tweets containing the drug 
names were obtained from Twitter’s Advanced Search engine. While the FAERS data were specific to ADRs, the Twitter data 
were more limited. Only hydrocodone/acetaminophen, prednisone, amoxicillin, gabapentin, and metformin had a sufficient 
volume of ADR content for review and comparison. For metformin, diarrhea was the side effect that resulted in no difference 
between the two platforms (P=.30). For hydrocodone/acetaminophen, ineffectiveness as an ADR that resulted in no difference 
(P=.60). For gabapentin, there were no differences in terms of the ADRs ineffectiveness and fatigue (P=.15 and P=.67, respectively). 
For amoxicillin, hypersensitivity, nausea, and rash shared similar profiles between platforms (P=.35, P=.05, and P=.31, 
respectively). 
Conclusions: FAERS and Twitter shared similarities in types of data reported and a few unique items to each data set as well. 
The use of Twitter as an ADR pharmacovigilance platform should continue to be studied as a unique and complementary source 
of information rather than a validation tool of existing ADR databases. 
(JMIR Public Health Surveill 2020;6(3):e19266) doi: 10.2196/19266 
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Introduction 
Background 
Adverse drug reactions (ADRs) are the unintended effect of 
medicine at doses used for prophylaxis, diagnosis, or treatment 
[1]. ADRs can occur anytime when a patient takes a medication. 
Factors including drug and food interactions, medication errors, 
allergies, and metabolism contribute to the occurrence of ADRs. 
ADRs have been identified as one of the leading causes of death 
in the United States. ADRs resulted in more deaths than the 
pulmonary diseases, diabetes, HIV/AIDS, and pneumonia [2,3]. 
A systematic review on ADR-induced hospital admissions found 
that 5.3% of hospital admissions were associated with ADRs 
[4]. New drug therapies, the aging population, and polypharmacy 
expose the population to increased risks of ADRs [5]. The 
burden of ADRs necessitates appropriate detection and 
assessment, and reporting is fundamental to successful 
pharmacovigilance systems. 
The US Food and Drug Administration (FDA) Adverse Event 
Reporting System (FAERS) is a database for reports of adverse 
events, medication errors, and product quality complaints [6]. 
Although FAERS serves as a valuable data source for 
postmarket pharmacovigilance, only drug manufacturers are 
required to send reports received from health care professionals 
and consumers to the FDA. Health care professionals and 
consumers may voluntarily submit reports, which may lead to 
incomplete data in FAERS. In order to obtain more 
comprehensive information on drug products, multiple data 
sources should be used to fill the information gap. 
Social media has been proposed as a potential data source as it 
allows an easily accessible information sharing platform with 
almost no chronological and geographical constraints. A 
systematic review of 51 studies compared ADR reports on social 
media and other pharmacovigilance systems, and the review 
noted that the prevalence of all ADR reports ranged from 0.2% 
to 8% and social media contained more reports of mild ADRs 
than severe ADRs [7]. Previous studies showed that ADRs were 
underrepresented in clinical trial data, and less severe ADRs 
were more frequently reported on social media. Social media 
ADR reports reflected the ADRs reported on FAERS on average 
11 months earlier [8,9]. Comparative studies suggested the 
practicality of using social media as a complementary resource 
and demonstrated a moderate agreement on ADR data between 
social media and FAERS [10,11]. These studies have shed light 
on the role of social media in ADR reporting. However, many 
studies only examined one or two less commonly used 
pharmaceutical agents, and some included more than 1000 
drugs. While the inclusion tested a general scheme of social 
media reporting, it overlooked the role of social media reporting 
for common drugs. 
The Center for Medication Safety Advancement (CMSA) at 
Purdue University College of Pharmacy aims to adopt previous 
research strategies and compare ADR reports in social media 
and FAERS. Twitter was selected as the social media for 
evaluation thanks to its simplicity and timeliness in information 
sharing and access. Twitter users can report an ADR in one 
tweet pursuant to the FDA guideline, which requires as a 
minimum dataset to constitute a viable report an identifiable 
patient, an identifiable reporter, a product exposure, and an 
adverse event [12]. Additionally, the FDA does not require 
reports to demonstrate causation or to be specific regarding the 
type of error. All suspected medication errors, ADRs, or adverse 
events are accepted as reports. Given the advantage of the 
Twitter database, the objective of this study is to validate the 
accuracy and precision of the research methodology and conduct 
evaluations of social media ADR reporting via tweets for 
commonly used pharmaceutical agents. 
Ethics Statement 
All social media data used in data collection and analysis were 
extracted from public sources. Example tweets were paraphrased 
and edited to prevent unmasking through a reverse search on 
Twitter. FAERS reports on SafeRx were also anonymized. As 
data used in this study were publicly available, no institutional 
review board approval was sought. 
Methods 
Overview 
This study was divided into 3 sections: drug selection, FAERS 
data collection, and Twitter data collection. Collecting FAERS 
data included searching for ADR reports of a pharmaceutical 
agent and calculating relative frequencies of the 5 most 
frequently reported ADRs, whereas Twitter data collection 
required an additional step to identify relevant tweets according 
to inclusion and exclusion criteria. Figure 1 demonstrates the 
overall scheme for the methodology of this study. 
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Figure 1. Methodology scheme. ADR: adverse drug reaction; FAERS: FDA Adverse Event Reporting System. 
Pharmaceutical Agents 
To identify the 10 most popular prescribed medications, 
prescription data were used from GoodRx, a health care 
company that operates a telemedicine platform. GoodRx 
generates a list of the top 10 drugs from monthly claims 
submitted by pharmacies in the United States; in November 
2017, those drugs were hydrocodone/acetaminophen, 
levothyroxine, prednisone, lisinopril, amoxicillin, gabapentin, 
metformin, atorvastatin, alprazolam, and amlodipine [13]. 
Previous studies included both brand and generic names in data 
collection to expand the data that could be obtained [10,14]. 
Some studies further suggested that patients tended to use the 
most common brand name in social media if a drug had multiple 
brand names [15,16]. Accordingly, this study included common 
brand names in the searching criteria as Twitter users could be 
discussing ADRs using common brand names. For the data 
collection purpose of this study, the most commonly used brand 
name for each selected drug was identified according to 
Micromedex: Norco for hydrocodone/acetaminophen, Synthroid 
for levothyroxine, Deltasone for prednisone, Prinivil for 
lisinopril, Amoxil for amoxicillin, Neurontin for gabapentin, 
Glucophage for metformin, Lipitor for atorvastatin, Xanax for 
alprazolam, and Norvasc for amlodipine. 
US Food and Drug Administration Adverse Event 
Reporting System Data 
Purdue University College of Pharmacy’s CMSA designed and 
maintained a searchable database for all published FAERS 
reports since 2012 under SafeRx. SafeRx enables large-scale 
studies to improve prescription medication safety as the database 
contains a collection of 4,935,048 ADRs, representing 294,652 
different drugs from the fourth quarter of 2012 through 
December 2016. ADR reports were obtained via the FAERS 
Data Explore function in SafeRx. The search criteria were set 
to display data from March 1, 2016, to March 31, 2017, and the 
data included both brand and generic names of selected drugs 
as the primary suspect and the secondary suspect drug. After 
obtaining all ADR reports from SafeRx, the 5 most reported 
ADRs for each selected drug were recorded for data analysis. 
Twitter Data 
Searchability and generalizability were the main factors in 
selecting Twitter as the social media platform. Twitter’s search 
engine enabled keyword-based searching within a predetermined 
time frame, and all public tweets containing the keyword could 
be displayed. According to the Pew Research Center, Twitter 
users were diverse in terms of age distribution and well balanced 
in terms of gender and geographic areas at the time of study in 
2016  [17] .  As  med ica t ions  inc lud ing  
hydrocodone/acetaminophen, prednisone, levothyroxine could 
be prescribed to individuals from all age groups regardless of 
gender and geographic areas, Twitter’s population represented 
a robust data source for generalizability. 
Tweets were obtained from the Advanced Search webpage on 
Twitter’s website [18]. Both generic and brand names of the 
selected medication were entered as keywords into the “any of 
these words” field in the Advanced Search engine. To exclude 
tweets containing advertisements, hyperlinks to external 
webpages, and retweets, characters including “rt” for retweets, 
“http,” and “.com” were entered into the “none of these words” 
field. By eliminating tweets from pharmaceutical companies, 
health care marketers, and agencies, Twitter data became more 
comparative to the FAERS data. Table 1 describes additional 
exclusion criteria in the selection of tweets. The “written in” 
field was set so that only tweets in the English language would 
be displayed. The time frame was chosen to be from March 
2016 to March 2017 in order to correspond with the FAERS 
data obtained from CMSA’s SafeRx database. All tweets 
displayed were subsequently reviewed to include only those 
that described ADRs after consuming the medication. Those 
tweets served as the final source for data recording, which 
included the username, offending medication, content of the 
tweet, and types of ADRs. At the time of data collection, the 
number of tweets was benchmarked at 100 for analysis. 
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Table 1. Additional exclusion criteria in the collection of tweets. 
Exclusion criteria Examples 
“He slept for a whole night like he took 20 Xanax” ADRsa described a metaphorical narration instead of a true patient experience. 
ADRs occurred long before the date of tweeting. “Lipitor gave me muscle aches when I took it 10 years ago” 
Tweet was a part of copied lyrics, lines from books, and other forms of liter- “Xanax got me sleeper. Leanin’ by the liter” 
ature. 
Tweet did not include the 4 minimal requirements to construct a report. Tweets lacking the person who was reporting, the person who experi-
enced the ADR, name of the drug, and the actual ADR. 
aADR: adverse drug reaction. 
Statistical Analysis 
The analysis of ADR data from SafeRx and Twitter included 
the following components: calculation of relative frequencies, 
examination of ADR distribution, and test for association and 
independence. A chi-square test was used to statistically quantify 
the difference in ADRs between the FAERS data and Twitter 
data. It was appropriate to use the chi-square test as no cell in 
the cross-tabulation contained an expected value of 5 or below. 
The sample size required to achieve an a priori α<.01 was 96, 
and samples from both sources exceeded the threshold. The null 
hypothesis (H0) was “there is no significant difference between 
FAERS data and Twitter data on common ADRs.” The failure 
to reject H0 would signify that Twitter data were similar to and 
independent from the FAERS data. The statistical analysis in 
this study was conducted using SAS version 9.4 (SAS Institute 
Inc). 
Results 
US Food and Drug Administration Adverse Event 
Reporting System Data Result 
A total of 40,539 FAERS ADR reports from March 1, 2016, to 
March 31, 2017, were obtained via SafeRx. Table 2 summarizes 
the 5 most reported ADRs for each of the 10 drugs. 
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Table 2. Five most frequently reported FDA Adverse Event Reporting System adverse drug reactions from March 1, 2016, to March 31, 2017, for each 
selected drug on SafeRx. 
Drug and the top 5 adverse drug reactions n (%) 
Hydrocodone/acetaminophen (Norco, n=1765) 
Ineffectiveness 429 (24.31) 
Nausea 371 (21.02) 
Fatigue 353 (20.00) 
Pain 345 (19.55) 
Headache 267 (15.13) 
Levothyroxine (Synthroid, n=3728) 
Fatigue 881 (23.63) 
Ineffectiveness 828 (22.21) 
Nausea 733 (19.66) 
Headache 664 (17.81) 
Diarrhea 622 (16.68) 
Prednisone (Deltasone, n=5689) 
Ineffectiveness 1423 (25.01) 
Fatigue 1332 (23.41) 
Dyspnea 1067 (18.76) 
Nausea 976 (17.16) 
Diarrhea 900 (15.82) 
Lisinopril (Prinivil, n=5386) 
Ineffectiveness 1243 (23.08) 
Fatigue 1172 (21.76) 
Diarrhea 1136 (21.09) 
Nausea 1062 (19.72) 
Dyspnea 773 (14.35) 
Amoxicillin (Amoxil, n=797) 
Hypersensitivity 328 (41.15) 
Fatigue 126 (15.81) 
Diarrhea 123 (15.43) 
Nausea 121 (15.18) 
Rash 99 (12.42) 
Gabapentin (Neurontin, n=5734) 
Ineffectiveness 1637 (28.55) 
Fatigue 1220 (21.28) 
Nausea 997 (17.40) 
Pain 966 (16.85) 
Diarrhea 914 (15.94) 
Metformin (Glucophage, n=5109) 
Hyperglycemia 1311 (25.66) 
Nausea 1111 (21.75) 
Ineffectiveness 973 (19.04) 
Diarrhea 919 (18.00) 
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Drug and the top 5 adverse drug reactions n (%) 
Fatigue 795 (15.56) 
Atorvastatin (Lipitor, n=6588) 
Type 2 diabetes 4601 (69.84) 
Hypersensitivity 586 (8.89) 
Fatigue 537 (8.15) 
Ineffectiveness 445 (6.75) 
Nausea 419 (6.36) 
Alprazolam (Xanax, n=2551) 
Ineffectiveness 561 (21.99) 
Fatigue 548 (21.48) 
Nausea 547 (21.44) 
Anxiety 451 (17.68) 
Headache 444 (17.40) 
Amlodipine (Norvasc, n=3192) 
Diarrhea 696 (21.80) 
Fatigue 682 (21.37) 
Ineffectiveness 636 (19.92) 
Nausea 611 (19.14) 
Dyspnea 567 (17.76) 
Twitter Data Result 
More than 40,000 tweets containing the drug names as keywords 
from March 1, 2016, to March 31, 2017, were obtained from 
Twitter’s Advanced Search engine. Although searching on 
Twitter yielded an overall large quantity of tweets, ADRs of 
some drugs were simply not mentioned in enough tweets. Within 
the study period, searching keywords levothyroxine and 
Synthroid yielded 50 relevant tweets, keywords alprazolam and 
Xanax resulted in 35 relevant tweets, lisinopril and Prinivil were 
found in 33 relevant tweets, and only 3 relevant tweets were 
found for atorvastatin and Lipitor. No relevant tweets were 
found for keywords amlodipine and Norvasc. Due to the 
insufficiency of relevant tweets to meet the benchmark, the final 
Twitter data analysis did not include levothyroxine, alprazolam, 
lisinopril, atorvastatin, and amlodipine. Table 3 presents the 
ADRs reported for the remaining 5 drugs. 
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Table 3. Reported adverse drug reactions on Twitter from March 1, 2016, to March 31, 2017, for 5 drugs. 
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Increased appetite 23 
Mood changes 10 
Moon face 8 
Weight gain 8 
Fatigue 5 
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Weight gain 8 
Dizziness 5 
Nausea 2 





Mood changes 1 












Mood changes 1 
Vomiting 1 
Drug and Adverse Drug Reaction Matching 
The process was completed through consolidating the ADRs 
reported in the Twitter dataset to match the top 5 ADRs from 
SafeRx. Following the matching, a chi-square test was 
performed to test nonsignificant differences in the relative 
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with that of FAERS, one should fail to reject H0 according to 
the P value from the chi-square test. Table 4 shows matched 
ADRs between the two data sources, relative frequencies of 
ADRs of each drug, and the results of chi-square test. 
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Table 4. Matched adverse drug reactions and chi-square test results for 5 drugs. 
Drug and adverse drug events Relative frequencies, Chi-square P value Relative frequencies, FAERSa data (%) 
Twitter data (%) 
Hydrocodone/acetaminophen 
Ineffectiveness 24.31 22.00 0.3 .60b 
Nausea 21.02 9.00 5.3 .02 
Fatigue 20.00 36.00 14.7 <.001 
Headache 15.13 2.00 13.2 <.001 
Prednisone 
Fatigue 23.41 5.00 18.8 <.001 
Dyspnea 18.76 1.00 47.0 <.001 
Amoxicillin 
Hypersensitivity 41.15 46.00 0.9 .35b 
Diarrhea 15.43 5.00 7.9 .005 
Nausea 15.18 8.00 3.8 .05b 
Fatigue 15.81 3.00 11.8 <.001 
Rash 12.42 16.00 1.0 .31b 
Gabapentin 
Ineffectiveness 28.55 22.00 2.1 .15b 
Fatigue 21.28 23.00 0.2 .68b 
Nausea 17.40 2.00 16.4 <.001 
Metformin 
Nausea 21.75 57.00 70.1 <.001 
Ineffectiveness 19.04 5.00 12.7 <.001 
Diarrhea 18.00 22.00 1.1 .30b 
Fatigue 15.56 3.00 11.9 <.001 
aFAERS: US Food and Drug Administration Adverse Event Reporting System. 
bIndicates a P value above .05, leading to the failure of rejecting the null hypothesis and indicating that there is no difference in ADR frequency reported 
between FAERS and Twitter. 
Discussion 
Principal Findings 
Among the 5 drugs in the final analysis, a number of Twitter 
ADR relative frequencies were not significantly different from 
those of FAERS ADRs. For metformin, diarrhea was one of the 
side effects. As no significant difference was detected between 
FAERS and Twitter data on diarrhea (P=.30), it showed that 
Twitter ADR reports could be further studied for their use as a 
c omp l emen t a r y  ADR da t a s e t .  I n  t h e  
hydrocodone/acetaminophen group, there were no significant 
differences in ineffectiveness between sources (P=.60). 
Gabapentin was shown to comparatively result in ineffectiveness 
and fatigue according to FAERS and Twitter (P=.15 and P=.67, 
respectively). Three ADRs of amoxicillin, hypersensitivity, 
nausea, and rash, shared similar profiles on FAERS and Twitter 
(P=.35, P=.05, and P=.31, respectively). 
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ADRs remain one of the leading causes for preventable hospital 
admissions, reduced quality of life, increased financial burdens 
in the society, and mortality [19]. Prevention relies on adherence 
to evidence-based medicine, monitoring, medication therapy 
management, and pharmacogenomic testing [20]. Management 
of ADRs should emphasize effective prevention and timely
detection, yet the current ADR reporting mechanism has shown 
delays in detection [21]. The cause for delays is multifactorial. 
Consumers might not know about such a reporting system, and 
the reporting steps could be troublesome. Further, as clinicians 
and patients are not required to report ADRs, many could be 
underreported. Social media and online resources have been 
proposed as additional resources for pharmacovigilance. In 
2017, MacKinlay et al [22] evaluated ADRs of 3055 drugs on 
Twitter and found that Twitter had up to 72% precision of ADR 
detection. By extracting ADRs of erlotinib, nivolumab, and 
pembrolizumab through social health networks, Nikfarjam et 
al [23] detected that social media ADRs were comparable and 
7 months ahead of ADRs from literature reports. Along with 
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numerous major publications on validating ADR reports across 
different social media platforms, Hoang et al [24] took a step 
further and incorporated content authenticity and user credibility 
to improve ADR detection on Twitter. With more advanced 
technology for data mining and ADR detection, social media 
can serve as an additional channel for monitoring ADRs. 
In this study, 10 drugs were identified, and ADR reports of these 
drugs on Twitter were retrospectively obtained by searching for 
tweets containing the drug names that mentioned ADR 
experiences. While adopting comparative methods used in 
previous studies, this study specifically focused on the 10 most 
commonly prescribed drugs to investigate if discrepancies 
existed pursuant to different drugs. Based on the results of this 
study, FAERS data and Twitter data showed some similar ADR 
profiles for hydrocodone/acetaminophen, amoxicillin, 
gabapentin, and metformin. In the data collection process, 
levothyroxine, alprazolam, lisinopril, and atorvastatin did not 
appear as keywords in sufficient tweets from March 1, 2016, 
to March 31, 2017. A possible explanation of the low number 
of tweets is the demographics of patients taking these 
medications. Atorvastatin, a lipid-lowering agent, is usually 
initiated for elderly patients, as are the antihypertensive agents 
lisinopril and amlodipine. Individuals aged 50 to 64 years and 
those older than 65 years represented 21% and 10% of all 
Twitter users, respectively [16]. Fewer Twitter users in these 
age ranges could potentially explain the low number of tweets 
for those drugs. The number of reports of these 3 drugs on 
FAERS further demonstrates that the lack of tweets was due to 
fewer users, as atorvastatin, lisinopril, and amlodipine had 6588, 
5386, and 3192 reports on FAERS. Other social media–based 
studies have also experienced this challenge and achieved 
opposite conclusions due to inactivity for most of the drugs 
studied on social media [25,26]. Nevertheless, data from the 
remaining drugs indicates the potential role of Twitter as a 
complementary source of ADR reporting to FAERS. 
The similarities observed for some ADRs between Twitter and 
FAERS data were disparate across the individual drugs studied. 
This variability further suggests that patients’actual experiences 
with medications are not being shared with their providers or 
that providers have not reported these experiences to national 
ADR repositories at a similar rate. Moreover, the insufficiency 
of tweets for some drugs may indicate that social media ADR 
reporting should consider drug classes and the demographics 
of patients taking them. One recommendation is to further 
investigate social media ADR reporting for drugs that are 
consumed by a population that represents a large share of social 
media users and drugs that require early ADR detection. 
In addition to being a supplementary data source for 
pharmacovigilance services, social media can also serve as a 
resource for pharmaceutical companies, regulatory bodies, 
researchers, health care professionals, patients, and 
policymakers. In this study, ineffectiveness appeared as an ADR 
for hydrocodone/acetaminophen, gabapentin, and metformin 
on both data sources. Gabapentin, for example, takes time to 
exert its full effect in controlling neurological pain. As 23.00% 
of Twitter ADRs and 28.55% of FAERS ADRs for gabapentin 
were ineffectiveness, it should encourage prescribers and 




the medication and seeing its effect. This study result should 
also prompt patient education on regular monitoring and diet 
adjustment when managing diabetes, as ineffectiveness for an 
antidiabetic drug, metformin, was 19.04% and 5.00% of all 
ADRs on FAERS and Twitter, respectively. Data mining to 
track ineffectiveness for hydrocodone/acetaminophen may offer 
a potential avenue for regulatory bodies in examining opioid 
use patterns. 
Limitations 
This study does have two prominent limitations: sample size 
and search methodology. Among multiple social media 
platforms, only Twitter was selected as the data source. Despite 
Twitter’s users being from multiple age groups, patients may 
choose to share their ADR experiences on other sites such as 
Facebook, Instagram, Reddit, and online forums, which 
prevented this study from examining social media data across 
different platforms. Additionally, due to Twitter’s privacy 
setting, private tweets are not searchable, which can reduce the 
number of tweets for data collection. The sample size of tweets 
obtained for the drugs was relatively small compared with that 
of FAERS reports from March 1, 2016, to March 31, 2017. The 
sample size could be largely increased in future studies as 
Twitter contains a large collection of tweets. During the search 
process, the keywords hydrocodone/acetaminophen and Norco 
yielded more than 100 tweets in the time period, which could 
potentially improve the accuracy of Twitter ADR data. However, 
there was a lack of relevant tweets for 4 of the 10 drugs, even 
with the benchmark of 100 tweets. This situation could 
potentially be resolved by extending the time frame to more 
than 1 year; however, the extent of sample size improvement 
might not be significant given the low number of social media 
users when studying specific drugs such as atorvastatin and 
amlodipine. 
Regarding the search mechanism, only one common brand name 
per drug was used to search for tweets, yet many drugs have 
multiple brand names. Lisinopril is sold under the brand names 
Prinivil and Zestril, and levothyroxine has brand names 
Synthroid, Levoxyl, and Thyrax. Using only one brand name 
in the study could limit the number of tweets obtained in this 
study, as patients might have shared their ADRs by using the 
brand names that were not included in this study. Other 
challenges to gathering all tweets through keywords include 
typographical errors, abbreviations, and unstructured lexicons. 
Furthermore, social media intrinsically bears a limitation in 
terms of patient follow-up. So far, research methodology 
involving social media pharmacovigilance has yet to be capable 
of investigating the causes of ADRs, the consequences of ADRs, 
and the actions taken to resolve ADRs. Some challenges are 
being tackled by computational technologies. For example, text 
normalization and classification through machine learning have 
been investigated by Sarker et al [27], and they offered insights 
into processing text data on social media. Other challenges of 
social media ADR reporting may continue to be barriers for 
taking full advantage of this data source. 
Although social media cannot replace professional reporting 
systems such as FAERS at this stage, studies including this 
analysis have indicated the role of social media as a tool for 
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early detection and a reporting system for mild symptoms. To 
demonstrate the accuracy and usability of social media ADR 
data in complementing FAERS, future studies may benefit by 
using a larger sample of data, including specific drugs, and 
assessing multiple social media platforms. It is also important 
to apply technology, along with structured reporting systems, 
to avoid arbitrary entries to better provide health care 
professionals, regulatory bodies, patients, and pharmaceutical 
companies with robust ADR data. 
Zhou & Hultgren 
Conclusion 
While the use of Twitter as an ADR reporting platform has 
limitations, should be considered as a unique and complementary 
source of information rather than a validation tool of an existing 
ADR database. Future research should focus on validating 
Twitter and other social media platforms using involving larger 
sample sizes and different medications. Additionally, evaluating 
the types of ADRs on social media that share the most similarity 
with those on FAERS would be helpful to promote effective 
use of this source of information. 
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